AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Akebia Q2 2025: Vafseo net product revenues at $13.3mln, total $60.5mln.
ByAinvest
Thursday, Aug 7, 2025 7:12 am ET2min read
• Akebia Therapeutics reports Q2 2025 net product revenues of $13.3 million • Total Q2 2025 net product revenues increase to $60.5 million • DaVita physicians to begin treating patients with Vafseo in August 2025 • Patient enrollment completed in VOICE clinical trial of Vafseo • Akebia to host Conference Call on August 7, 2025 • Digital data: Q2 2025 net product revenues increase 0.2% YoY • Digital data: Total Q2 2025 net product revenues increase 0.4% YoY
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on improving the lives of those impacted by kidney disease, reported robust financial results for the second quarter (Q2) of 2025. The company's net product revenues increased significantly, with Q2 2025 net product revenues reaching $13.3 million, up from $12.9 million in Q1 2025 [1]. This growth was driven by the continued expansion of Vafseo® (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor used to manage anemia in patients with chronic kidney disease (CKD) [2].Total Q2 2025 net product revenues increased to $60.5 million, marking a 0.4% year-over-year (YoY) increase [3]. This growth was primarily attributed to the strong performance of Vafseo and Auryxia® (ferric citrate), with Vafseo net product revenues accounting for $13.3 million and Auryxia net product revenues totaling $47.2 million [4].
DaVita, a leading dialysis organization serving more than 200,000 patients, is expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics [5]. This initiative aims to expand patient access to Vafseo and is part of Akebia's broader strategy to increase utilization at mid-sized dialysis organizations.
Patient enrollment in the VOICE clinical trial, a collaborative study of Vafseo designed to measure its non-inferiority to standard-of-care erythropoietin stimulating agents (ESAs), was completed in Q2 2025. The trial enrolled 2,116 patients and top-line data are expected in early 2027 [6].
Akebia is also working towards its goal of initiating the VALOR Phase 3 clinical trial to study the use of vadadustat for treating anemia in late-stage CKD patients who are not on dialysis by the end of this year. The company has requested a Type-C meeting with the U.S. Food and Drug Administration (FDA) to discuss the trial [7].
The company's financial results were bolstered by increased clinical trial activities related to Vafseo and other programs, as well as the expansion of Vafseo's use in dialysis clinics. Despite these advancements, Akebia faced challenges such as the loss of exclusivity for Auryxia and the non-cash expense related to the change in fair value of its warrant liability [8].
Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. Eastern Time to discuss its second quarter 2025 earnings. Interested parties can register for the call via the company's website [9].
References:
[1] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[2] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[3] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[4] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[5] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[6] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[7] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[8] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
[9] https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet